FindTrial
Sign In

Diagnostic study of early immune markers of progestin treatment of endometrial cancer and endometrial atypical hyperplasia

Study of the immune mechanism of progesterone in preservation fertility treatment of endometrial cancer and endometrial atypical hyperplasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061833
Enrollment
Unknown
Registered
2022-07-03
Start date
2021-09-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer and endometrial atypical hyperplasia

Interventions

case series:None

Sponsors

The First Affiliated Hospital of USTC
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The pathological type is type I endometrioid carcinoma, the pathological grade is no more than G2 or the pathology is atypical hyperplasia of endometrium; 2. The lesions did not infiltrate the deep muscle layer after MRI and ultrasound evaluation; 3. Aged <= 40 years, and the person with strong will is not more than 45 years old; 4. Normal liver and kidney function, no contraindications to hormone therapy; 5. There was further family planning about 1 year after treatment.

Exclusion criteria

Exclusion criteria: 1. Obvious contraindications; 2. The pathological type is non endometrioid carcinoma or the pathological grade exceeds G2; 3. FIGO stage of endometrial carcinoma exceeds stage IA.

Design outcomes

Primary

MeasureTime frame
Immune marker;Decidualization of endometrium;Pregnancy outcome;—

Countries

China

Contacts

Public ContactJieqi Ke

The First Affiliated Hospital of USTC

kejieqi@ustc.edu.cn+86 17855126186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026